Literature DB >> 31293180

A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.

Dong Wang1, Jiafu Feng2, Bei Xu2.   

Abstract

Aim: Platinum agents are DNA damaging agents with promising activity in breast cancers, especially in triple-negative subgroup. This meta-analysis was conducted to compare the treatments of platinum-based neoadjuvant chemotherapy (NAC) and standard NAC for triple-negative breast cancers (TNBCs). Materials & methods: Diverse electronic databases were searched to identify the randomized clinical trials that directly compared the treatments of platinum-based NAC versus NAC in TNBC patients. Toxicity of platinum-based regimens was further evaluated.
Results: Addition of platinum agents significantly improved the pathological complete response rates in TNBC patients compared with the standard NAC. Unfortunately, platinum-based regimens were more likely to develop higher incidence of hematologic toxicities.
Conclusion: Platinum-based NAC regimens could achieve significant pathological complete response improvement with well-tolerated toxicity in TNBC patients.

Entities:  

Keywords:  meta-analysis; neoadjuvant chemotherapy; pathological complete response; platinum agents; triple-negative breast cancer

Year:  2019        PMID: 31293180     DOI: 10.2217/fon-2019-0165

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

Review 1.  Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses.

Authors:  Jianyun Yin; Changtai Zhu; Gaofeng Wang; Jianwei Gu
Journal:  Int J Gen Med       Date:  2022-06-30

2.  Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.

Authors:  Benjamín Walbaum; Francisco Acevedo; Lidia Medina; M Loreto Bravo; Tomas Merino; Mauricio Camus; Francisco Dominguez; Sebastián Mondaca; Héctor Galindo; Bruno Nervi; Carolina Ibañez; Jorge Madrid; Sabrina Muñiz; José Peña; Érica Koch; Marcelo Garrido; Mauricio P Pinto; César Sánchez
Journal:  Ecancermedicalscience       Date:  2021-02-01

Review 3.  A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.

Authors:  Sonal Gandhi; Muriel Brackstone; Nicole J Look Hong; Debjani Grenier; Elysia Donovan; Fang-I Lu; Mia Skarpathiotakis; Justin Lee; Jean-Francois Boileau; Francisco Perera; Christine Simmons; Anil A Joy; William T Tran
Journal:  Breast Cancer Res Treat       Date:  2022-02-28       Impact factor: 4.872

Review 4.  Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.

Authors:  Jenny Furlanetto; Sibylle Loibl
Journal:  Breast Care (Basel)       Date:  2020-06-02       Impact factor: 2.860

5.  Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.

Authors:  Milos Holanek; Iveta Selingerova; Ondrej Bilek; Tomas Kazda; Pavel Fabian; Lenka Foretova; Maria Zvarikova; Radka Obermannova; Ivana Kolouskova; Oldrich Coufal; Katarina Petrakova; Marek Svoboda; Alexandr Poprach
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

Review 6.  A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer.

Authors:  Wuna Feng; Yujing He; Jingsi Xu; Hongya Zhang; Yuexiu Si; Jiaxuan Xu; Shengzhou Li
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.